Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors

被引：10

作者：

Switzer, Benjamin ^{[1
]}

Haanen, John ^{[2
]}

Lorigan, Paul C. ^{[3
,4
]}

Puzanov, Igor ^{[1
]}

Turajlic, Samra ^{[5
,6
,7
]}

机构：

[1] Roswell Park Comprehens Canc Ctr, Dept Med, Buffalo, NY 14203 USA

[2] Netherlands Canc Inst, Div Med Oncol, Amsterdam, Netherlands

[3] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[4] Christie NHS Fdn Trust, Div Med Oncol, Manchester, Lancs, England

[5] Royal Marsden NHS Fdn Trust, Renal Unit, London, England

[6] Royal Marsden NHS Fdn Trust, Skin Unit, London, England

[7] Francis Crick Inst, Canc Dynam Lab, London, England

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷 / 07期

基金：

英国医学研究理事会; 英国惠康基金;

关键词：

immunotherapy; COVID-19; melanoma; kidney neoplasms; vaccination; CANCER-PATIENTS; SUPPRESSOR-CELLS; VIRUS-INFECTION; MYELOID CELLS; T-CELLS; INFLAMMATION; VACCINE; INNATE; IMMUNOPATHOLOGY; IMMUNOTHERAPY;

D O I：

10.1136/jitc-2021-002835

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regarding the use of immune checkpoint inhibitors (ICIs) in patients with cancer during the SARS-CoV-2 pandemic, with a focus on patients with melanoma and renal cell carcinoma (RCC). More specifically, we summarize the theoretical concepts and available objective data regarding the relationships between ICIs and the antiviral immune response, along with recommended clinical approaches to the management of melanoma and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic. Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 vaccines and broader implications toward future pandemics are also discussed.

引用

页数：10

共 50 条

[41] Clinical outcomes of tyrosine kinase inhibitors immediately after immune checkpoint inhibitors in renal cell carcinoma
Kato, Taigo
Nagahara, Akira
Kawamura, Norihiko
Nakata, Wataru
Soda, Tetsuji
Matsuzaki, Kyousuke
Hatano, Koji
Kawashima, Atsunari
Ujike, Takeshi
Nishimura, Kensaku
Takada, Shingo
Tsujihata, Masao
Yamaguchi, Seiji
Takao, Tetsuya
Nakai, Yasutomo
Nakayama, Masashi
Uemura, Motohide
Nonomura, Norio
ANNALS OF ONCOLOGY, 2022, 33 : S497 - S497
[42] Immune-checkpoint inhibitors from cancer to COVID-19: A promising avenue for the treatment of patients with COVID-19 (Review)
Vivarelli, Silvia
Falzone, Luca
Torino, Francesco
Scandurra, Giuseppa
Russo, Giulia
Bordonaro, Roberto
Pappalardo, Francesco
Spandidos, Demetrios A.
Raciti, Giuseppina
Libra, Massimo
INTERNATIONAL JOURNAL OF ONCOLOGY, 2021, 58 (02) : 145 - 157
[43] COVID-19 vaccination status and clinical outcomes in solid cancer patients treated with immune checkpoint inhibitors.
Khaddour, Karam
Meeder, Natalie
Kamel, Josette Mary
Babwah, Amaara
Nguyen, Ryan Huu-Tuan
Wang, Heidy
Liu, Li C.
Feldman, Lawrence Eric
Jain, Shikha
Weinberg, Frank
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18731 - E18731
[44] Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors
Wu, Qiuji
Chu, Qian
Zhang, Hongyan
Yang, Bin
He, Xudong
Zhong, Yahua
Yuan, Xianglin
Chua, Melvin L. K.
Xie, Conghua
CANCER COMMUNICATIONS, 2020, 40 (08) : 374 - 379
[45] The treatment of Merkel cell carcinoma with immune checkpoint inhibitors: implications for patients with rheumatoid arthritis
Klee, Gina
Kisch, Tobias
Kuempers, Christiane
Perner, Sven
Schinke, Susanne
Zillikens, Detlef
Langan, Ewan A.
Terheyden, Patrick
RHEUMATOLOGY ADVANCES IN PRACTICE, 2021, 5 (03)
[46] Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma
Yuki Nemoto
Hiroki Ishihara
Kazutaka Nakamura
Hidekazu Tachibana
Hironori Fukuda
Kazuhiko Yoshida
Hirohito Kobayashi
Junpei Iizuka
Hiroaki Shimmura
Yasunobu Hashimoto
Kazunari Tanabe
Tsunenori Kondo
Toshio Takagi
International Urology and Nephrology, 2022, 54 : 47 - 54
[47] Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma
Nemoto, Yuki
Ishihara, Hiroki
Nakamura, Kazutaka
Tachibana, Hidekazu
Fukuda, Hironori
Yoshida, Kazuhiko
Kobayashi, Hirohito
Iizuka, Junpei
Shimmura, Hiroaki
Hashimoto, Yasunobu
Tanabe, Kazunari
Kondo, Tsunenori
Takagi, Toshio
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (01) : 47 - 54
[48] Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors
Chahoud, Jad
Msaouel, Pavlos
Ross, Jeremy A.
McCormick, Barrett Z.
Bathala, Tharakeswara K.
Gao, Jianjun
Horn, Robert
Xiao, Lianchun
Sircar, Kanishka
Campbell, Matthew T.
Shah, Amishi Y.
Goswami, Sangeeta
Zurita, Amado J.
Jonasch, Eric
Matin, Surena F.
Wood, Christopher G.
Karam, Jose A.
Sharma, Padmanee
Tannir, Nizar M.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (02) : 134.e9 - 134.e16
[49] Comparison of outcomes between patients of African and European descent with metastatic renal cell carcinoma receiving immune checkpoint inhibitors.
Kaur, Jasmeet
Hasler, Jill S.
Handorf, Elizabeth A.
Zibelman, Matthew R.
Geynisman, Daniel M.
Plimack, Elizabeth R.
Ghatalia, Pooja
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 369 - 369
[50] Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Martini, Dylan J.
Goyal, Subir
Liu, Yuan
Evans, Sean T.
Olsen, T. Anders
Case, Katherine
Magod, Benjamin L.
Brown, Jacqueline T.
Yantorni, Lauren
Russler, Greta Anne
Caulfield, Sarah
Goldman, Jamie M.
Nazha, Bassel
Harris, Wayne B.
Kissick, Haydn T.
Master, Viraj A.
Kucuk, Omer
Carthon, Bradley C.
Bilen, Mehmet Asim
ONCOLOGIST, 2021, 26 (10): : E1742 - E1750

← 1 2 3 4 5 →